CDT Equity Inc. (NASDAQ:CDT) Short Interest Down 45.3% in August

CDT Equity Inc. (NASDAQ:CDT) saw a large decrease in short interest during the month of August. As of August 14th, there was short interest totaling 9,954 shares, a decrease of 45.3% from the July 30th total of 18,200 shares. Based on an average daily volume of 79,218 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.4% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of CDT Equity in a research note on Wednesday, June 24th. Wall Street Zen raised shares of CDT Equity from a “sell” rating to a “hold” rating in a research report on Saturday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

CDT Equity Stock Down 10.1%

NASDAQ:CDT traded down $0.17 on Tuesday, hitting $1.51. The stock had a trading volume of 92,125 shares, compared to its average volume of 285,301. CDT Equity has a 52 week low of $1.47 and a 52 week high of $2,719.40. The business’s fifty day moving average is $3.79 and its 200 day moving average is $50.57. The company has a market cap of $1.19 million, a PE ratio of -0.00 and a beta of 1.52.

CDT Equity (NASDAQ:CDT) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($8.71) EPS for the quarter.

CDT Equity Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.